Phenyl Propionic Acid

Phenyl Propionic Acid

SCHEMBL235064

O=C(O)CCc1ccccc1.O=C(O)CCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 1.00
FFAR1 O14842 13/20 0.91
HDAC2 Q92769 2/20 0.74
HDAC8 Q9BY41 2/20 0.74
HDAC6 Q9UBN7 2/20 0.74
HDAC3 O15379 1/20 0.74
MAPK1 P28482 1/20 0.74
ADRA1A P35348 1/20 0.74
HDAC4 P56524 1/20 0.74
SLC6A3 Q01959 1/20 0.74
HDAC1 Q13547 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
HDAC7 Q8WUI4 1/20 0.74
HDAC10 Q969S8 1/20 0.74
HDAC11 Q96DB2 1/20 0.74
HDAC9 Q9UKV0 1/20 0.74
HDAC5 Q9UQL6 1/20 0.74
MAPT P10636 1/20 0.68
RXFP1 Q9HBX9 1/20 0.68
FFAR4 Q5NUL3 5/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenyl Propionic Acid SCHEMBL3419 1.00 KEAP1 (1.00) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL27523271 1.00 KEAP1 (1.00) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL13618844 1.00 KEAP1 (1.00) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL29619843 1.00 KEAP1 (1.00) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL10878208 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL8901632 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL3478262 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL9122761 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL2067973 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6
Phenyl Propionic Acid SCHEMBL2468015 0.97 KEAP1 (0.95) KEAP1FFAR1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023199324-A1 MIXTURE OF 3-HEXENYL ESTER ISOMERS AND USES THEREOF AGAN AROMA & FINE CHEMICALS LTD. (IL) 2023-10-19 WO claimed
EP-3087969-B1 PROTEASOME INHIBITORS AND USES THEREOF ARBISER JACK L (US) 2021-06-30 EP claimed
CN-109438238-B Synthetic method of dihydrocinnamate compound 陕西师范大学 2021-04-13 CN claimed
US-20180325854-A1 USE OF PROTEASOME INHIBITORS TO TREAT OCULAR DISORDERS ACCUITIS PHARMACEUTICALS INC (US) 2018-11-15 US claimed
EP-3370709-A1 USE OF PROTEASOME INHIBITORS TO TREAT OCULAR DISORDERS Accuitis Pharmaceuticals, Inc. (US) 2018-09-12 EP claimed
EP-2951313-B1 BIOMARKERS RELATED TO INSULIN RESISTANCE PROGRESSION AND METHODS USING THE SAME METABOLON INC (US) 2018-03-07 EP claimed
WO-2017078953-A1 USE OF PROTEASOME INHIBITORS TO TREAT OCULAR DISORDERS ACCUITIS PHARMACEUTICALS, INC. (US) 2017-05-11 WO claimed
EP-3087969-A1 PROTEASOME INHIBITORS AND USES THEREOF Arbiser, Jack L. (US) 2016-11-02 EP claimed
US-8809283-B2 Proteasome inhibitors and uses thereof NATUDERM, LLC (US) 2014-08-19 US claimed
EP-1895971-A2 PROTEASOME INHIBITORS AND USES THEREOF Arbiser, Jack (US) 2008-03-12 EP claimed
US-20070004647-A1 Proteasome inhibitors and uses thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-01-04 US claimed
WO-2006127525-A2 PROTEASOME INHIBITORS AND USES THEREOF ARBISER JACK (US) 2006-11-30 WO claimed
US-20060167045-A1 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist MERCK & CO., INC. 2006-07-27 US claimed
EP-1545540-A2 COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST Merck & Co., Inc. (US) 2005-06-29 EP claimed
WO-2004017896-A2 COMBINATION THERAPY USING A DUAL PPAR ALPHA/GAMMA AGONIST AND AN ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST MERCK & CO., INC. (US) 2004-03-04 WO claimed
EP-3710462-B1 BRARTEMICIN ANALOGUES VICTORIA LINK LTD (NZ) 2026-05-13 EP disclosed
US-20250004378-A1 Pattern Forming Method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2025-01-02 US disclosed
US-4558130-A FLUORESCENCE ON OXIDATION BY HYDROGEN PEROXIDE; PEROXIDASE DETERMINATION MILES LABORATORIES, INC. (US) 1985-12-10 US disclosed
EP-0156261-A2 Fluorogenic dihydroquinolone and dihydrocoumarin indicators for hydrogen peroxide MILES INC. (US) 1985-10-02 EP disclosed
EP-0121743-A2 Optical indicator chalcogen compounds and use MILES LABORATORIES, INC. (US) 1984-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167045-A1 Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin II type I receptor antagonist AGTR2, AGTR1, PPARA KEAP1 2058/4885FFAR1 15/4885HDAC2 665/4885
US-20070004647-A1 Proteasome inhibitors and uses thereof PSMB5, PSMB1, PSMA5 KEAP1 67/4885FFAR1 4104/4885HDAC2 489/4885
US-20180325854-A1 USE OF PROTEASOME INHIBITORS TO TREAT OCULAR DISORDERS PSMC1, PSMB1, PSMG3 KEAP1 42/4885FFAR1 1959/4885HDAC2 95/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.